ID: ALA4453313

Max Phase: Preclinical

Molecular Formula: C18H13Cl2N3

Molecular Weight: 342.23

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C#CCNc1ccc2nc(C)c(-c3ccc(Cl)c(Cl)c3)nc2c1

Standard InChI:  InChI=1S/C18H13Cl2N3/c1-3-8-21-13-5-7-16-17(10-13)23-18(11(2)22-16)12-4-6-14(19)15(20)9-12/h1,4-7,9-10,21H,8H2,2H3

Standard InChI Key:  GBTOKXYINGUQOJ-UHFFFAOYSA-N

Associated Targets(non-human)

Astrocyte 64 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 342.23Molecular Weight (Monoisotopic): 341.0487AlogP: 4.96#Rotatable Bonds: 3
Polar Surface Area: 37.81Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 2.75CX LogP: 4.37CX LogD: 4.37
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.68Np Likeness Score: -1.61

References

1. Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B..  (2016)  New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.,  59  (13): [PMID:27341519] [10.1021/acs.jmedchem.6b00297]

Source